Anti-HIV and anti-HCV small molecule protease inhibitors in-silico repurposing against SARS-CoV-2 M^pro for the treatment of COVID-19

References

• Abraham, M. J., van der Spoel, D., Lindahl, E., Hess, B., & The GROMACS Development Team. (2015). GROMACS User Manual version 5.1.1. www.gromacs.org
   Google Scholar
• Alamri, M. A., Tahir Ul Qamar, M., Mirza, M. U., Bhadane, R., Alqahtani, S. M., Muneer, I., Froeyen, M., & Salo-Ahen, O. M. H. (2021). Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro. Journal of Biomolecular Structure & Dynamics, 39(13), 4936–4948. https://doi.org/10.1080/07391102.2020.1782768
   PubMed Web of Science ®Google Scholar
• Al-Khafaji, K., Al-Duhaidahawi, D., & Taskin Tok, T. (2021). Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. Journal of Biomolecular Structure & Dynamics, 39(9), 3387–3395. https://doi.org/10.1080/07391102.2020.1764392
   PubMed Web of Science ®Google Scholar
• Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. (2001). Electrostatics of nanosystems: Application to microtubules and the ribosome. Proceedings of the National Academy of Sciences of the United States of America, 98(18), 10037–10041. https://doi.org/10.1073/pnas.181342398
   PubMed Web of Science ®Google Scholar
• Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the treatment of covid-19 – Final report. New England Journal of Medicine, 383(19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Bello, M., Martínez-Muñoz, A., & Balbuena-Rebolledo, I. (2020). Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA. Journal of Molecular Modeling, 26(12), 340. https://doi.org/10.1007/s00894-020-04600-4
   PubMed Web of Science ®Google Scholar
• Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, S. (2021). Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. Journal of Biomolecular Structure & Dynamics, 39(10), 3449–3458. https://doi.org/10.1080/07391102.2020.1766572
   PubMed Web of Science ®Google Scholar
• Boreak, N. (2021). Small molecule "silmitasertib" repurposed as inhibitor of transforming growth factor beta 1 for the development of therapeutics for oral submucous fibrosis. BioMed Research International, 2021, 6631848. https://doi.org/10.1155/2021/6631848
   PubMed Web of Science ®Google Scholar
• Cheatham, T. E., Miller, J. L., Fox, T., Darden, T. A., & Kollman, P. A. (1995). Molecular dynamics simulations on solvated biomolecular systems: The particle mesh ewald method leads to stable trajectories of DNA, RNA, and proteins. Journal of the American Chemical Society, 117(14), 4193–4194. https://doi.org/10.1021/ja00119a045
   Web of Science ®Google Scholar
• Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet, 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., & Corey, L. (1996). Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New England Journal of Medicine, 334(16), 1011–1017. https://doi.org/10.1056/NEJM199604183341602
   PubMed Web of Science ®Google Scholar
• Dierynck, I., Van Marck, H., Van Ginderen, M., Jonckers, T. H. M., Nalam, M. N. L., Schiffer, C. A., Raoof, A., Kraus, G., & Picchio, G. (2011). TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrobial Agents and Chemotherapy, 55(12), 5723–5731. https://doi.org/10.1128/AAC.00748-11
   PubMed Web of Science ®Google Scholar
• Elfiky, A. A. (2020). Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 253, 117592. https://doi.org/10.1016/j.lfs.2020.117592
   PubMed Web of Science ®Google Scholar
• Galindez, G., Matschinske, J., Rose, T. D., Sadegh, S., Salgado-Albarrán, M., Späth, J., Baumbach, J., & Pauling, J. K. (2021). Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nature Computational Science, 1(1), 33–41. https://doi.org/10.1038/s43588-020-00007-6
   PubMedGoogle Scholar
• Gorbalenya, A. E., Baker, S. C., & Baric, R. S. (2020). The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology, 5, 536–544. https://doi.org/10.1038/s41564-020-0695-z.
   PubMed Web of Science ®Google Scholar
• Hall, D. C., Jr., & Ji, H. F. (2020). A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Medicine and Infectious Disease, 35, 101646. https://doi.org/10.1016/j.tmaid.2020.101646
   PubMed Web of Science ®Google Scholar
• Hegyi, A., & Ziebuhr, J. (2002). Conservation of substrate specificities among coronavirus main proteases. The Journal of General Virology, 83(Pt 3), 595–599. https://doi.org/10.1099/0022-1317-83-3-595
   PubMedGoogle Scholar
• https://go.drugbank.com
   Google Scholar
• https://pubchem.ncbi.nlm.nih.gov
   Google Scholar
• Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582(7811), 289–293. https://doi.org/10.1038/s41586-020-2223-y
   PubMed Web of Science ®Google Scholar
• Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., Zhu, Y., Zhu, C., Hu, T., Du, X., Duan, Y., Yu, J., Yang, X., Yang, X., Yang, K., Liu, X., Guddat, L. W., Xiao, G., Zhang, L., Yang, H., & Rao, Z. (2020). Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nature Structural & Molecular Biology, 27(6), 529–532. https://doi.org/10.1038/s41594-020-0440-6
   PubMed Web of Science ®Google Scholar
• Jo, S., Kim, S., Shin, D. H., & Kim, M. S. (2020). Inhibition of SARS-CoV 3CL protease by flavonoids. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 145–151. https://doi.org/10.1080/14756366.2019.1690480
   PubMed Web of Science ®Google Scholar
• Johansson, M. U., Zoete, V., Michielin, O., & Guex, N. (2012). Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics, 13, 173. https://doi.org/10.1186/1471-2105-13-173
   PubMed Web of Science ®Google Scholar
• Keating, G. M. (2016). Elbasvir/Grazoprevir: First global approval. Drugs, 76(5), 617–624. https://doi.org/10.1007/s40265-016-0558-3
   PubMed Web of Science ®Google Scholar
• Khan, F. I., Lai, D., Anwer, R., Azim, I., & Khan, M. K. A. (2020). Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 172–186. https://doi.org/10.1080/14756366.2019.1692828
   PubMed Web of Science ®Google Scholar
• Kumar, S., Zhi, K., Mukherji, A., & Gerth, K. (2020). Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19. Viruses, 12(5), 486. https://doi.org/10.3390/v12050486
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Lynn, A., & Open Source Drug Discovery Consortium. (2014). g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962., . https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Kuzmanic, A., & Zagrovic, B. (2010). Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. Biophysical Journal, 98(5), 861–871. https://doi.org/10.1016/j.bpj.2009.11.011
   PubMed Web of Science ®Google Scholar
• Kwong, A. D., Kauffman, R. S., Hurter, P., & Mueller, P. (2011). Discovery and development of telaprevir: An NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nature Biotechnology, 29(11), 993–1003. https://doi.org/10.1038/nbt.2020
   PubMed Web of Science ®Google Scholar
• Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., … Feng, Z. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine, 382(13), 1199–1207. https://doi.org/10.1056/NEJMoa2001316
   PubMed Web of Science ®Google Scholar
• Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., La Marca, A., & Leonard, J. M. (1995). A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. The New England Journal of Medicine, 333(23), 1534–1539. https://doi.org/10.1056/NEJM199512073332204
   PubMed Web of Science ®Google Scholar
• Martin, S. (2020). Homology models of Wuhan coronavirus 3CLpro protease. ChemRxiv. https://doi.org/10.26434/chemrxiv.11637294
   Google Scholar
• McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020). Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 157, 104859. https://doi.org/10.1016/j.phrs.2020.104859
   PubMed Web of Science ®Google Scholar
• Molla, A., Mo, H., Vasavanonda, S., Han, L., Lin, C. T., Hsu, A., & Kempf, D. J. (2002). In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrobial Agents and Chemotherapy, 46(7), 2249–2253. https://doi.org/10.1128/AAC.46.7.2249-2253.2002
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Mueller, B. U., Sleasman, J., Nelson, R. P., Smith, S., Deutsch, P. J., Ju, W., Steinberg, S. M., Balis, F. M., Jarosinski, P. F., Brouwers, P., Mistry, G., Winchell, G., Zwerski, S., Sei, S., Wood, L. V., Zeichner, S., & Pizzo, P. A. Jr. (1998). A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics, 102(1), 101–109. https://doi.org/10.1542/peds.102.1.101
   PubMed Web of Science ®Google Scholar
• Oroguchi, T., & Nakasako, M. (2016). Changes in hydration structure are necessary for collective motions of a multi-domain protein. Scientific Reports, 6, 26302. https://doi.org/10.1038/srep26302
   PubMed Web of Science ®Google Scholar
• Pillaiyar, T., Manickam, M., Namasivayam, V., Hayashi, Y., & Jung, S.-H. (2016). An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy. Journal of Medicinal Chemistry, 59(14), 6595–6628. https://doi.org/10.1021/acs.jmedchem.5b01461
   PubMed Web of Science ®Google Scholar
• Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., DiNubile, M. J., Sniukiene, V., Brass, C. A., Albrecht, J. K., & Bronowicki, J.-P. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine, 364(13), 1195–1206. https://doi.org/10.1056/NEJMoa1010494
   PubMed Web of Science ®Google Scholar
• Robinson, B. S., Riccardi, K. A., Gong, Y. F., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., & Lin, P. F. (2000). BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrobial Agents and Chemotherapy, 44(8), 2093–2099. https://doi.org/10.1128/AAC.44.8.2093-2099.2000
   PubMed Web of Science ®Google Scholar
• Rodier, F., Bahadur, R. P., Chakrabarti, P., & Janin, J. (2005). Hydration of protein-protein interfaces. Proteins: Structure, Function, and Bioinformatics, 60(1), 36–45. https://doi.org/10.1002/prot.20478
   PubMed Web of Science ®Google Scholar
• Rosenquist, Å., Samuelsson, B., Johansson, P.-O., Cummings, M. D., Lenz, O., Raboisson, P., Simmen, K., Vendeville, S., de Kock, H., Nilsson, M., Horvath, A., Kalmeijer, R., de la Rosa, G., & Beumont-Mauviel, M. (2014). Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. Journal of Medicinal Chemistry, 57(5), 1673–1693. https://doi.org/10.1021/jm401507s
   PubMed Web of Science ®Google Scholar
• Sadler, B. M., Hanson, C. D., Chittick, G. E., Symonds, W. T., & Roskell, N. S. (1999). Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrobial Agents and Chemotherapy, 43(7), 1686–1692. https://doi.org/10.1128/AAC.43.7.1686
   PubMed Web of Science ®Google Scholar
• Salmaso, V., & Moro, S. (2018). Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Frontiers in Pharmacology, 9, 923. https://doi.org/10.3389/fphar.2018.00923
   PubMed Web of Science ®Google Scholar
• Schüttelkopf, A. W., & van Aalten, D. M. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica. Section D, Biological Crystallography, 60(Pt 8), 1355–1363. https://doi.org/10.1107/S0907444904011679
   PubMedGoogle Scholar
• Sisay, M. (2020). 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials. Pharmacological Research, 156, 104779. https://doi.org/10.1016/j.phrs.2020.104779
   PubMed Web of Science ®Google Scholar
• Sultan, A., Ali, R., Sultan, T., Ali, S., Khan, N. J., & Parganiha, A. (2021). Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 Mpro for pharmacological interventions in COVID-19 pandemic. Chronobiology International, 38(7), 971–985. https://doi.org/10.1080/07420528.2021.1903027
   PubMed Web of Science ®Google Scholar
• Surleraux, D. L. N. G., Tahri, A., Verschueren, W. G., Pille, G. M. E., de Kock, H. A., Jonckers, T. H. M., Peeters, A., De Meyer, S., Azijn, H., Pauwels, R., de Bethune, M.-P., King, N. M., Prabu-Jeyabalan, M., Schiffer, C. A., & Wigerinck, P. B. T. P. (2005). Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. Journal of Medicinal Chemistry, 48(6), 1813–1822. https://doi.org/10.1021/jm049560p
   PubMed Web of Science ®Google Scholar
• Taylor, J. G., Zipfel, S., Ramey, K., Vivian, R., Schrier, A., Karki, K. K., Katana, A., Kato, D., Kobayashi, T., Martinez, R., Sangi, M., Siegel, D., Tran, C. V., Yang, Z.-Y., Zablocki, J., Yang, C. Y., Wang, Y., Wang, K., Chan, K., … Link, J. O. (2019). Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®. Bioorganic & Medicinal Chemistry Letters, 29(16), 2428–2436. https://doi.org/10.1016/j.bmcl.2019.03.037
   PubMed Web of Science ®Google Scholar
• Turner, S. R., Strohbach, J. W., Tommasi, R. A., Aristoff, P. A., Johnson, P. D., Skulnick, H. I., Dolak, L. A., Seest, E. P., Tomich, P. K., Bohanon, M. J., Horng, M. M., Lynn, J. C., Chong, K. T., Hinshaw, R. R., Watenpaugh, K. D., Janakiraman, M. N., & Thaisrivongs, S. (1998). Tipranavir (PNU-140690): A potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry, 41(18), 3467–3476. https://doi.org/10.1021/jm9802158
   PubMed Web of Science ®Google Scholar
• Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2020). Clinical management of COVID-19: Interim guidance. https://reliefweb.int/sites/reliefweb.int/files/resources/2005_clinical_management_of_covid-19-v7.pdf
   Google Scholar
• Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., Sheng, J., Quan, L., Xia, Z., Tan, W., Cheng, G., & Jiang, T. (2020). Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe, 27(3), 325–328. https://doi.org/10.1016/j.chom.2020.02.001
   PubMed Web of Science ®Google Scholar
• Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/10.1038/s41586-020-2008-3
   PubMed Web of Science ®Google Scholar
• Yadav, D. K., & Kumar, S., S. (2018). Molecular insights into the interaction of RONS and Thieno[3,2-c]pyran analogs with SIRT6/COX-2: A molecular dynamics study. Scientific Reports, 8(1), 4777. https://doi.org/10.1038/s41598-018-22972-9
   PubMed Web of Science ®Google Scholar
• Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., Gao, G. F., Anand, K., Bartlam, M., Hilgenfeld, R., & Rao, Z. (2003). The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 100(23), 13190–13195. https://doi.org/10.1073/pnas.1835675100
   PubMed Web of Science ®Google Scholar
• Zhang, K. E., Wu, E., Patick, A. K., Kerr, B., Zorbas, M., Lankford, A., Kobayashi, T., Maeda, Y., Shetty, B., & Webber, S. (2001). Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities. Antimicrobial Agents and Chemotherapy, 45(4), 1086–1093. https://doi.org/10.1128/AAC.45.4.1086-1093.2001
   PubMed Web of Science ®Google Scholar
• Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science, 368(6489), 409–412. https://doi.org/10.1126/science.abb3405
   PubMed Web of Science ®Google Scholar
• Zhong, H., Wang, Y., Zhang, Z.-L., Liu, Y.-X., Le, K.-J., Cui, M., Yu, Y.-T., Gu, Z.-C., Gao, Y., & Lin, H.-W. (2020). Efficacy and safety of current therapeutic options for COVID-19 – Lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacological Research, 157, 104872. https://doi.org/10.1016/j.phrs.2020.104872
   PubMed Web of Science ®Google Scholar
• Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., … Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar